Explore the next era of coronary intravascular lithotripsy featuring innovative technology for calcium modification. This session covers the unique mechanism of action, practical application in complex cases, and recent clinical evidence supporting its safety and efficacy.

This session introduces the novel Hertz Contact intravascular lithotripsy system, designed for effective calcium fragmentation without trade-offs. It covers lesion types amenable to treatment, system mechanism, optimization tips, and discusses real-world cases along with supporting clinical trial evidence.

• Multi-modality simulation to unveil the hidden parts & small obstacles that can result in complications
• Angioscopy directly inside the coronary artery to provide a better understanding of 3D stent configuration

Commented by Goran Stankovic and William Wijns

Part 1 of a 3-part series.
Next episode: How to correct incomplete crush and...

• Differentiating between complete and incomplete crush
• The importance of sequential crush and bigger balloons, adequately sized according to proximal vessel diameter

Commented by Goran Stankovic and William Wijns

Part 2 of a 3-part series:  
Previous episode: DK Crush like you’ve never seen it before
Coming up next: Main vessel stenting in DK-Crush, lessons...

View the case of this 65-year-old male patient who was staged for R-PCI of a Medina 1,1,1 distal left main lesion, and discover how the authors used a hybrid robotic and manual approach to perform a DK crush procedure using the second-generation R-PCI device.

This article reviews the current evidence on TAVI durability, focusing on long-term outcomes, device-specific considerations, and the implications for lifetime management strategies.

Mirvat Al Asnag provides her take on the ALL-RISE randomised trial presented by Ajay J. Kirtane at ACC.26 in New Orleans.

Authored by Hector Garcia-Garcia and Jorge Sanz-Sanchez, this article examines pivotal randomized clinical trials on drug-coated balloons in coronary artery disease. It highlights their role in managing in-stent restenosis, de novo small vessel lesions, and large vessel lesions while exploring future directions through ongoing trials.